Illumina, Inc. (NASDAQ:ILMN) Shares Bought by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,372 shares of the life sciences company's stock after buying an additional 3,309 shares during the period. IFM Investors Pty Ltd's holdings in Illumina were worth $2,568,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Capital World Investors boosted its holdings in Illumina by 408.6% during the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after buying an additional 14,481,232 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Illumina by 54,220.9% during the fourth quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after purchasing an additional 1,909,118 shares in the last quarter. Norges Bank purchased a new position in Illumina during the fourth quarter valued at $228,714,000. Bessemer Group Inc. lifted its holdings in Illumina by 32,837.5% during the fourth quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock valued at $180,152,000 after purchasing an additional 1,344,038 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in Illumina by 2,057.5% during the first quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company's stock valued at $73,174,000 after purchasing an additional 879,533 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Illumina Price Performance

Shares of NASDAQ ILMN traded up $0.13 on Friday, hitting $100.18. The company's stock had a trading volume of 327,695 shares, compared to its average volume of 2,147,072. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a market capitalization of $15.86 billion, a price-to-earnings ratio of -16.49, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.86 and a quick ratio of 1.48. The stock has a 50 day moving average of $86.75 and a 200-day moving average of $96.72.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the prior year, the firm earned $0.98 earnings per share. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. Morgan Stanley reduced their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Barclays reiterated an "underweight" rating and issued a $85.00 target price (up from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and cut their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday. Scotiabank cut shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective for the company. in a research report on Friday. Finally, Royal Bank Of Canada dropped their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $125.11.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.